Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.

Romero-Gómez M, Armstrong MJ, Funuyet-Salas J, Mangla KK, Ladelund S, Sejling AS, Shrestha I, Sanyal AJ

Alimentary pharmacology & therapeutics16 Jun 2023Cited by 23 (Europe PMC)

PMID37328931DOI10.1111/apt.17598PepBankPUB-37328931

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, semaglutide improved the SF-36 physical component summary score versus placebo at 72 weeks (ETD 4.26).
In plain wordsIn adults with NASH, semaglutide improved the physical part of quality of life more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 physical component summary score at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
4.26 score points
PCS
Source sentences
Summary
At 72 weeks, semaglutide was associated with significant improvements in physical component summary (PCS) score (estimated treatment difference [ETD] 4.26; 95% confidence interval [CI]: 1.96-6.55; p = 0.0003)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893101
02HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, semaglutide improved the SF-36 bodily pain score versus placebo at 72 weeks (ETD 5.07).
In plain wordsIn adults with NASH, semaglutide improved the bodily pain score more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 bodily pain at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
5.07 score points
bodily pain
Source sentences
Summary
bodily pain (ETD 5.07; 95% CI: 2.15-7.99; p = 0.0007)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893102
03HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, semaglutide improved SF-36 physical functioning versus placebo at 72 weeks (ETD 3.51).
In plain wordsIn adults with NASH, semaglutide improved physical functioning more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 physical functioning at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
3.51 score points
physical functioning
Source sentences
Summary
physical functioning (ETD 3.51; 95% CI: 1.16-5.86; p = 0.0034)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893103
04HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, semaglutide improved the SF-36 score for role limitations due to physical health problems versus placebo at 72 weeks (ETD 2.80).
In plain wordsIn adults with NASH, semaglutide reduced physical health limits on daily roles more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 role limitations due to physical health at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
2.8 score points
role limitations physical
Source sentences
Summary
role limitations due to physical health problems (ETD 2.80; 95% CI: 0.28-5.33; p = 0.0294)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893104
05HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, semaglutide improved SF-36 social functioning versus placebo at 72 weeks (ETD 3.16).
In plain wordsIn adults with NASH, semaglutide improved social functioning more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 social functioning at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
3.16 score points
social functioning
Source sentences
Summary
social functioning (ETD 3.16; 95% CI: 0.53-5.78; p = 0.0183)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893105
06HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, semaglutide improved SF-36 vitality versus placebo at 72 weeks (ETD 4.47).
In plain wordsIn adults with NASH, semaglutide improved vitality more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36 vitality at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
4.47 score points
vitality
Source sentences
Summary
vitality (ETD 4.47; 95% CI: 1.63-7.32; p = 0.0021)
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893106
07HumanRandomized controlled trialEfficacy outcome
In adults with biopsy-proven NASH, the SF-36 mental component summary score did not differ significantly between semaglutide and placebo (ETD 1.02).
In plain wordsIn adults with NASH, semaglutide did not change the mental part of quality of life compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeSF-36 mental component summary score at 72 weeks
Study
n = 320
Comparator
Placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
0.1, 0.2 or 0.4 mg once daily · subcutaneous · 72 weeksAs given in this study (human).
Measurements
Estimated treatment difference
1.02 score points
MCS
Source sentences
Summary
There was no significant difference in the mental component summary score (ETD 1.02; 95% CI: -1.59 to 3.62; p = 0.4441).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
Report a problemFND-3732893107

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

08HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with NASH, physical component summary improvements were greater in patients with NASH resolution than without, pooling semaglutide and placebo.
In plain wordsIn adults with NASH, physical quality of life improved more in people whose NASH resolved, whether they took semaglutide or placebo.
Peptide
Semaglutide
Outcome
IncreasePhysical component summary improvement by NASH resolution
Study
n = 320
Comparator
Patients without NASH resolution
Analysis
Secondary
Outcome group
Quality of life · Whole body
Source sentences
Summary
After 72 weeks, improvements in PCS scores were significantly greater in patients (pooled semaglutide and placebo) with NASH resolution than without (p = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
Adults with biopsy-proven NASH and stage 1-3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks.
Summary · context
Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3732893108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02970942

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Novo Nordisk A/Sn = 32030 Nov 2016 to 19 Mar 2020

Hepatobiliary Disorders · Non-alcoholic Steatohepatitis

Trial page ClinicalTrials.govUpdated 16 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.